Palvella Therapeutics Inc (PVLA) has a current Price-to-Book (P/B) ratio of 28.75. Compared to its 3-year average P/B ratio of 10.56, the current P/B ratio is approximately 172.15% higher. Relative to its 5-year average P/B ratio of 10.56, the current P/B ratio is about 172.15% higher. Palvella Therapeutics Inc (PVLA) has a Forward Free Cash Flow (FCF) yield of approximately -2.15%. Compared to its 3-year average FCF yield of -4.06%, the current FCF yield is approximately -47.15% lower. Relative to its 5-year average FCF yield of -4.06%, the current FCF yield is about -47.15% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PVLA competitors is 8916.10, providing a benchmark for relative valuation. Palvella Therapeutics Inc Corp (PVLA.O) exhibits a P/S ratio of 53466.81, which is 499.67% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PVLA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PVLA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PVLA currently overvalued or undervalued?

What is Palvella Therapeutics Inc (PVLA) fair value?

PVLA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Palvella Therapeutics Inc (PVLA) is between to according to relative valuation method.

How does PVLA's valuation metrics compare to the industry average?

The average P/S ratio for PVLA's competitors is 8916.10, providing a benchmark for relative valuation. Palvella Therapeutics Inc Corp (PVLA) exhibits a P/S ratio of 53466.81, which is 499.67% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Palvella Therapeutics Inc (PVLA) as of Mar 02 2026?

As of Mar 02 2026, Palvella Therapeutics Inc (PVLA) has a P/B ratio of 28.75. This indicates that the market values PVLA at 28.75 times its book value.

What is the current FCF Yield for Palvella Therapeutics Inc (PVLA) as of Mar 02 2026?

As of Mar 02 2026, Palvella Therapeutics Inc (PVLA) has a FCF Yield of -2.15%. This means that for every dollar of Palvella Therapeutics Inc's market capitalization, the company generates -2.15 cents in free cash flow.

What is the current Forward P/E ratio for Palvella Therapeutics Inc (PVLA) as of Mar 02 2026?

As of Mar 02 2026, Palvella Therapeutics Inc (PVLA) has a Forward P/E ratio of -25.63. This means the market is willing to pay $-25.63 for every dollar of Palvella Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Palvella Therapeutics Inc (PVLA) as of Mar 02 2026?

As of Mar 02 2026, Palvella Therapeutics Inc (PVLA) has a Forward P/S ratio of 53466.81. This means the market is valuing PVLA at $53466.81 for every dollar of expected revenue over the next 12 months.

PVLA Valuation